Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cells in prostate and prostate cancer development.

John S Lam1, Robert E Reiter

  • 1Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA 90095, USA.

Urologic Oncology
|March 8, 2006
PubMed
Summary

Cancer stem cells drive tumor growth and resistance. Targeting these cells and their self-renewal offers a promising new strategy for improving prostate cancer treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Head-to-head Comparison of Multimodal Imaging for Prostate Cancer Detection and Local Staging with Whole-mount Histopathology Reference.

European urology oncology·2026
Same author

Burnout in Urology is a Quality of Care Problem, and Joy in Work is the Solution.

Urology practice·2026
Same author

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis.

Lancet (London, England)·2026
Same author

Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial.

European urology oncology·2025

Area of Science:

  • Oncology
  • Stem Cell Biology
  • Cancer Research

Background:

  • Cancers are heterogeneous, containing diverse cell populations with varying proliferative and regenerative potentials.
  • Cancer stem cells (CSCs) are a small subset of tumor cells exhibiting self-renewal, a key stem cell property.
  • Shared signaling pathways between normal stem cells and CSCs suggest a biological link.

Purpose of the Study:

  • To present a stem cell model for prostate cancer based on normal and abnormal prostate growth differentiation pathways.
  • To explore the role of CSCs in prostate cancer development and treatment.

Main Methods:

  • Review of differentiation pathways in normal and abnormal prostate development.
  • Analysis of evidence linking CSCs to prostate cancer initiation and progression.

Related Experiment Videos

  • Development of a conceptual model for prostate cancer based on stem cell properties.

    • Main Results:

    • Prostate cancer may arise from the malignant transformation of prostate epithelial stem/progenitor cells.
    • These transformed cells exhibit resistance to apoptosis and promote tumor proliferation.
    • A stem cell model provides a new framework for understanding prostate cancer.

    Conclusions:

    • The proposed stem cell model significantly impacts the study and treatment of prostate cancer.
    • Targeting CSCs and their dysregulated self-renewal mechanisms holds potential for enhanced therapeutic strategies.
    • This approach may lead to improved treatment outcomes for prostate cancer patients.